3320.HK实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 11:59):

Stats
今日成交量	6.69M
平均成交量	9.19M
市值	32.29B
EPS	HKD0 ( 2024-03-27 )
Last Dividend	HKD0.160 ( 2023-06-05 )
Next Dividend	HKD0 ( N/A )
P/E	7.79
ATR14	HKD0.00700 (0.14%)

音量相关性

長: 0.15 (neutral)

短: 0.00 (neutral)

Signal:(57.146) Neutral

China Resources 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

China Resources 相关性 - 货币/商品

-0.50
( neutral )

-0.42
( neutral )

0.00
( neutral )

0.62
( weak )

China Resources 财务报表

Annual	2023
营收:	HKD270.40B
毛利润:	HKD42.36B (15.67 %)
EPS:	HKD0.680

FY	2023
营收:	HKD270.40B
毛利润:	HKD42.36B (15.67 %)
EPS:	HKD0.680

FY	2022
营收:	HKD254.11B
毛利润:	HKD39.13B (15.40 %)
EPS:	HKD0.660

FY	2021
营收:	HKD236.81B
毛利润:	HKD35.38B (14.94 %)
EPS:	HKD0.600

Financial Reports:

No articles found.

China Resources Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.160 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

China Resources Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 8.46 - good (84.60%) | Divividend Growth Potential Score: 4.24 - Stable (15.18%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.0900	2017-05-24
Last Dividend	HKD0.160	2023-06-05
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	8	--
Total Paid Out	HKD0.980	--
Avg. Dividend % Per Year	0.00%	--
Score	2.49	--
Div. Sustainability Score	8.46
Div.Growth Potential Score	4.24
Div. Directional Score	6.35	--

Next Divdend (Est)
(2025-03-31)

HKD0.175 Estimate 3.10 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.49

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
9928.HK	Ex Dividend Junior	2023-06-02	Annually	0.00%
2180.HK	Ex Dividend Knight	2023-07-03	Annually	0.00%
1181.HK	Ex Dividend Knight	2023-09-13	Annually	0.00%
0257.HK	Ex Dividend Junior	2023-09-25	Semi-Annually	0.00%
3888.HK	Ex Dividend Junior	2023-06-02	Annually	0.00%
1755.HK	Ex Dividend Knight	2023-07-03	Annually	0.00%
0798.HK	Ex Dividend Junior	2023-06-20	Annually	0.00%
2338.HK	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
1313.HK	Ex Dividend Junior	2023-09-14	Semi-Annually	0.00%
0373.HK	Ex Dividend Junior	2023-05-04	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0158	1.500	9.68	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0156	1.200	9.48	10.00	[0 - 0.3]
returnOnEquityTTM	0.0800	1.500	-0.222	-0.334	[0.1 - 1]
payoutRatioTTM	0.245	-1.000	7.55	-7.55	[0 - 1]
currentRatioTTM	1.330	0.800	8.35	6.68	[1 - 3]
quickRatioTTM	0.799	0.800	-0.00494	-0.00395	[0.8 - 2.5]
cashRatioTTM	0.236	1.500	9.80	10.00	[0.2 - 2]
debtRatioTTM	0.313	-1.500	4.79	-7.19	[0 - 0.6]
interestCoverageTTM	4.41	1.000	9.48	9.48	[3 - 30]
operatingCashFlowPerShareTTM	1.555	2.00	9.48	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.054	2.00	9.47	10.00	[0 - 20]
debtEquityRatioTTM	1.678	-1.500	3.29	-4.93	[0 - 2.5]
grossProfitMarginTTM	0.157	1.000	-0.722	-0.722	[0.2 - 0.8]
operatingProfitMarginTTM	0.0431	1.000	-1.139	-1.139	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.127	1.000	-0.407	-0.407	[0.2 - 2]
assetTurnoverTTM	0.992	0.800	6.72	5.38	[0.5 - 2]
Total Score				8.46

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	8.22	1.000	9.27	0	[1 - 100]
returnOnEquityTTM	0.0800	2.50	-0.143	-0.334	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.054	2.00	9.65	10.00	[0 - 30]
dividendYielPercentageTTM	3.17	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.555	2.00	9.48	10.00	[0 - 30]
payoutRatioTTM	0.245	1.500	7.55	-7.55	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0399	1.000	-1.502	0	[0.1 - 0.5]
Total Score				4.24

China Resources

China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and Hong Kong. The company operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. It offers a range of chemical drugs, Chinese medicines, and biopharmaceutical drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular, alimentary tract, metabolism and endocrine, respiratory, orthopedics, oncology, medical nutrition, gastroenterology, pediatrics, genitourinary system, cough and cold, anti-infection, dermatology, infusion solutions, etc. The company also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it is involved in property holding activities. As of December 31, 2021, the company operated 801 retail pharmacies under the CR Care and Teck Soon Hong brands. It distributes its products to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.